News for STRATA Skin Sciences Inc (E2OM.BE)

Today's Daily Dose brings you news about the regulatory set back of Athenex's oral Paclitaxel and CorMedix's Defencath, ASLAN Pharma's Atopic Dermatitis trial results, FDA panel review of FibroGen's Roxadustat, Morphic Therapeutic's Phase 1 single ascending dose clinical trial of MORF-057, which is in development for the treatment of inflammatory bowel disease, and STRATA Skin's CEO transition.

HORSHAM, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) (the "Company") a medical technology company in dermatology and ...

HORSHAM, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company in dermatology and plastic surgery ...